Cerevance Appoints Naidong Ye, Ph.D. as Vice President and Head of Chemistry, Manufacturing and Controls
- Date 15 Feb 2021
Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of Naidong Ye, Ph.D., a seasoned chemist with extensive pharmaceutical industry experience, as vice president and head of chemistry, manufacturing and controls (CMC).
Prior to joining Cerevance, Dr. Ye served as vice president of CMC for Millendo Therapeutics, a clinical stage biopharmaceutical company focused on developing novel treatments for endocrine diseases. While at Millendo, Dr. Ye was responsible for all CMC-related activities, including two late-stage programs. Before Millendo, Dr. Ye was senior director, head of CMC operations for AstraZeneca’s Neuroscience Innovative Medicines (NS iMed), where he led CMC operations for all small molecule development projects. In this role, Dr. Ye was responsible for projects ranging from candidate drug nomination to large scale, global pivotal trials. Earlier in his career, Dr. Ye served as chief technology officer for Dongguan Jinmeiji Pharmaceutical Co., and held leadership positions as both a scientist and CMC lead at several life sciences companies, including Pharmos Corporation, ViroPharma and Nycomed.